Evidence map›Paper›PMID 35950369›Full record

ArticleAnnals of clinical and translational neurology2022

The CBI-R detects early behavioural impairment in genetic frontotemporal dementia.

Annabel Nelson, Lucy L Russell, Georgia Peakman, Rhian S Convery, Arabella Bouzigues, Caroline V Greaves, Martina Bocchetta, David M Cash, John C van Swieten, Lize Jiskoot and 24 more

Abstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Caregiver perspectives enable accurate diagnosis of neurodegenerative disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Annabel NelsonDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Lucy L RussellDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0001-5023-5893
Georgia PeakmanDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Rhian S ConveryDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Arabella BouziguesDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Caroline V GreavesDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Martina BocchettaDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0003-1814-5024
David M CashDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
John C van SwietenDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Lize JiskootDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Fermin MorenoCognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain.
Raquel Sanchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.ORCID 0000-0001-7750-896X
Robert LaforceClinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, Canada.ORCID 0000-0002-2031-490X
Caroline GraffCenter for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.
Mario MasellisSunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
James B RoweDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Barbara BorroniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.ORCID 0000-0001-9340-9814
Elizabeth FingerDepartment of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.ORCID 0000-0003-4461-7427
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-2280-7273
Daniela GalimbertiFondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.ORCID 0000-0002-9284-5953
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Alexandre de MendonçaFaculty of Medicine, University of Lisbon, Lisbon, Portugal.
Chris R ButlerNuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
Alexander GerhardDivision of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
Simon DucharmeDepartment of Psychiatry, McGill University Health Centre, McGill University, Montreal, QC, Canada.ORCID 0000-0002-7309-1113
Isabelle Le BerSorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.ORCID 0000-0002-2508-5181
Isabel SantanaUniversity Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Florence PasquierUniv Lille, Lille, France.
Johannes LevinDepartment of Neurology, Ludwig-Maximilians Universität München, Munich, Germany.
Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany.
Sandro SorbiDepartment of Neurofarba, University of Florence, Florence, Italy.
Jonathan D RohrerDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-6155-8417
Genetic FTD Initiative (GENFI)

Funding

Department of Health BRC149/NS/MHMedical Research Council MR/M008525/1Medical Research Council MR/M023664/1Medical Research Council MR/T046015/1
6 · The paper itself

Abstract

introductionBehavioural dysfunction is a key feature of genetic frontotemporal dementia (FTD) but validated clinical scales measuring behaviour are lacking at present.

methodsWe assessed behaviour using the revised version of the Cambridge Behavioural Inventory (CBI-R) in 733 participants from the Genetic FTD Initiative study: 466 mutation carriers (195 C9orf72, 76 MAPT, 195 GRN) and 267 non-mutation carriers (controls). All mutation carriers were stratified according to their global CDR plus NACC FTLD score into three groups: asymptomatic (CDR = 0), prodromal (CDR = 0.5) and symptomatic (CDR = 1+). Mixed-effects models adjusted for age, education, sex and family clustering were used to compare between the groups. Neuroanatomical correlates of the individual domains were assessed within each genetic group.

resultsCBI-R total scores were significantly higher in all CDR 1+ mutation carrier groups compared with controls [C9orf72 mean 70.5 (standard deviation 27.8), GRN 56.2 (33.5), MAPT 62.1 (36.9)] as well as their respective CDR 0.5 groups [C9orf72 13.5 (14.4), GRN 13.3 (13.5), MAPT 9.4 (10.4)] and CDR 0 groups [C9orf72 6.0 (7.9), GRN 3.6 (6.0), MAPT 8.5 (13.3)]. The C9orf72 and GRN 0.5 groups scored significantly higher than the controls. The greatest impairment was seen in the Motivation domain for the C9orf72 and GRN symptomatic groups, whilst in the symptomatic MAPTgroup, the highest-scoring domains were Stereotypic and Motor Behaviours and Memory and Orientation. Neural correlates of each CBI-R domain largely overlapped across the different mutation carrier groups.

conclusionsThe CBI-R detects early behavioural change in genetic FTD, suggesting that it could be a useful measure within future clinical trials.

Indexed as

Frontotemporal DementiaPick Disease of the BrainC9orf72 ProteinHumansProgranulinstau ProteinsC9orf72 ProteinProgranulinstau Proteins

Identifiers

PMID35950369
PMCPMC9082390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.